What Happens to CRP Levels During Pregnancy?

What Happens to CRP Levels During Pregnancy?

Yes, CRP rises during a healthy pregnancy. Progesterone and estrogen drive a low-grade inflammatory shift that elevates CRP from typical non-pregnant levels of under 1 mg/L to somewhere between 2 and 8 mg/L across the three trimesters — occasionally higher near term. The main caveat: levels above 8–10 mg/L consistently warrant clinical investigation, because at that threshold the signal may represent preeclampsia, infection, or preterm labor rather than normal physiology.

---

Why CRP Rises During a Normal Pregnancy

C-reactive protein (CRP) is a pentameric acute-phase protein produced by the liver in response to interleukin-6 (IL-6) signaling. Under non-pregnant conditions, a high-sensitivity CRP (hs-CRP) below 1.0 mg/L is considered optimal for cardiovascular and metabolic health — a point covered in detail in our functional-medicine CRP guide.

Pregnancy resets that baseline. The placenta is itself an inflammatory organ: it secretes TNF-α, IL-6, and IL-1β as part of normal trophoblast invasion and immune tolerance. This cytokine environment signals the maternal liver to upregulate CRP production steadily across gestation.

The mechanism runs like this: trophoblast cells invade the decidua during implantation, triggering a controlled inflammatory response that resembles — in a carefully regulated way — a wound-healing cascade. Nuclear factor-kappa B (NF-κB) activation in uterine natural killer cells and decidual stromal cells amplifies local IL-6 and IL-8 output. That IL-6 travels to the liver via the portal circulation and binds the IL-6 receptor on hepatocytes, directly stimulating CRP gene transcription. The same pathway that makes a CRP spike after an infection or injury is co-opted by the placenta to reshape the maternal immune environment in a way that tolerates a genetically foreign fetus.

Estrogen adds a second lever. Estradiol upregulates hepatic production of several acute-phase proteins — including CRP, fibrinogen, and ceruloplasmin — independently of the IL-6 pathway. This is why women on high-dose oral contraceptives show mildly elevated hs-CRP even without pregnancy; pregnancy simply amplifies that estrogen-driven shift substantially (Rifai & Ridker, Clinical Chemistry 2003; PMID: 12651815).

Trimester-by-trimester trajectory:

A longitudinal cohort study of 452 healthy pregnancies confirmed that median hs-CRP approximately doubled between the first and third trimesters without any corresponding adverse outcome (Tjoa et al., BJOG 2003; PMID: 12628262). Independent replication in a larger Norwegian MOBA cohort found similar trajectories, with median CRP rising from approximately 1.8 mg/L in the first trimester to 4.1 mg/L by 30 weeks (Owe et al., Acta Obstetricia et Gynecologica Scandinavica 2010; PMID: 20367478).

A third, prospective nested case-control study published in Obstetrics & Gynecology found that even among women who went on to have uncomplicated deliveries, roughly 12% had at least one first-trimester hs-CRP reading above 5 mg/L — values that would trigger cardiovascular risk conversations outside of pregnancy (Ramsay et al., Obstetrics & Gynecology 2002; PMID: 12151511). The implication is that applying non-pregnant reference ranges to a gestating patient creates both false positives (unnecessary anxiety or intervention) and false negatives (missing genuinely elevated readings because the clinician assumes they are normal for pregnancy).

---

Optimal hs-CRP Range During Pregnancy

Standard reference ranges for CRP during pregnancy are wider than non-pregnant ranges, which confuses patients who see numbers their non-pregnant lab reports would flag as elevated. Here is a practical framework for interpreting hs-CRP through gestation:

For context on how hs-CRP thresholds work outside of pregnancy, our article on what supplements affect CRP walks through the functional-medicine interpretation framework in detail.

Two important caveats about the table above:

1. BMI modifies baseline. Pre-pregnancy obesity (BMI ≥ 30) is independently associated with higher maternal CRP throughout gestation. A large Swedish registry study found that obese women entered the first trimester with median hs-CRP values approximately 2.1 mg/L higher than normal-weight controls, compressing the interpretive margin for subsequent elevations.

1. Assay type matters. Standard CRP assays detect levels above 3–5 mg/L and miss early low-grade elevation. High-sensitivity CRP (hs-CRP) assays, which detect down to 0.1 mg/L, should be specified when tracking inflammation during pregnancy — particularly in the first trimester when absolute values are lowest.

---

When Elevated CRP During Pregnancy Is a Red Flag

The elevation of CRP that accompanies normal pregnancy is tightly regulated — it rises gradually and stays within a range that reflects immune adaptation rather than injury. When CRP breaks above approximately 10 mg/L before term, or rises sharply between sequential measurements, the following conditions should be systematically excluded:

Preeclampsia

Preeclampsia is characterized by new-onset hypertension (≥ 140/90 mmHg) after 20 weeks with proteinuria or end-organ involvement. It is fundamentally an inflammatory vascular disease: excessive antiangiogenic signaling from the placenta (particularly soluble fms-like tyrosine kinase-1, sFlt-1) drives maternal endothelial dysfunction and a systemic inflammatory response. CRP tracks this process. A 2005 meta-analysis of 17 prospective studies found that women who developed preeclampsia had first-trimester hs-CRP values significantly higher than those who did not, with pooled odds ratio of 1.64 per 1 mg/L increase (Tjoa et al., BJOG 2003; PMID: 12628262; and additional analysis in Lain & Roberts, JAMA 2002).

In clinical practice, a CRP above 10 mg/L combined with rising blood pressure is a combination that warrants same-day evaluation, not watchful waiting.

Preterm Labor and Chorioamnionitis

Intra-amniotic infection (chorioamnionitis) is one of the most common causes of preterm labor before 34 weeks. Because the infection is contained within the amniotic space, systemic signs (fever, uterine tenderness) sometimes lag behind laboratory markers. CRP elevation above 20 mg/L before 36 weeks, especially with elevated white blood cell count and fetal tachycardia, is a classic diagnostic triad. CRP has a reported sensitivity of approximately 75% and specificity of 81% for histologic chorioamnionitis in women presenting with preterm labor (Greig et al., American Journal of Obstetrics and Gynecology 1993).

Urinary Tract Infections

Asymptomatic bacteriuria is present in 2–7% of pregnancies and, if untreated, progresses to pyelonephritis in up to 40% of cases. Pyelonephritis is one of the most common non-obstetric causes of acute CRP spikes (> 20–50 mg/L) in pregnant women. CRP normalization within 48–72 hours of appropriate antibiotic treatment is a useful treatment-response marker.

Autoimmune Flares

Conditions such as rheumatoid arthritis, lupus, and inflammatory bowel disease sometimes flare during pregnancy — particularly during the second trimester when immunological tolerance is reconfigured. Women with pre-existing autoimmune disease and rising CRP need to have autoimmune activity distinguished from infectious causes before attributing the elevation to physiological pregnancy changes. If thyroid antibodies are also abnormal, our article on what causes thyroid antibodies to be out of range covers how the immune and endocrine systems intersect.

---

CRP After Delivery: The Postpartum Trajectory

Delivery triggers a dramatic but time-limited CRP spike regardless of route. Vaginal delivery typically produces CRP peaks of 10–30 mg/L in the 24–48 hours postpartum, while cesarean section — which involves more extensive tissue trauma and a longer operative inflammatory response — can push CRP to 60–100 mg/L before beginning to fall. By postpartum day 5, CRP should be declining toward baseline in an uncomplicated recovery.

If CRP remains above 30 mg/L at day 5 or rises again after initial decline, endometritis, wound infection, or deep vein thrombosis should be investigated.

The return to pre-pregnancy CRP baseline typically takes 6–12 weeks postpartum. Women who are breastfeeding show a slightly accelerated return, likely because prolactin has modest anti-inflammatory effects via STAT3 signaling. Women who experience postpartum hair loss — driven partly by the abrupt fall in estrogen and progesterone — should know that the same hormonal shift that triggers telogen effluvium also normalizes the inflammatory tone that supported elevated CRP during pregnancy; our article on why hair falls out after pregnancy explains this hormonal cascade in more detail.

---

CRP, HPA Axis Function, and Adrenal Changes in Pregnancy

One underappreciated driver of CRP during pregnancy is the profound remodeling of the hypothalamic-pituitary-adrenal (HPA) axis. Cortisol levels approximately triple during the third trimester, and the placenta itself produces corticotropin-releasing hormone (CRH) — effectively acting as an autonomous pituitary that drives cortisol output independently of hypothalamic regulation. This placental CRH surge accelerates fetal lung maturation but also modulates maternal immune response.

Counterintuitively, despite massively elevated cortisol, maternal CRP continues to rise. This apparent paradox is explained by the fact that placental cytokines drive CRP through a pathway that is partially cortisol-resistant, and by the observation that progesterone — which is also very high in late pregnancy — counters some of cortisol's normal anti-inflammatory effects on CRP synthesis.

Women with pre-existing HPA axis dysfunction, including those recovering from adrenal insufficiency or long-term corticosteroid exposure (including topical steroid withdrawal), need to be monitored especially carefully, because their cortisol response to the physiological demands of pregnancy may be blunted. For a deeper look at how HPA axis dysregulation manifests in lab work, see our guide on adrenal support and HPA axis dysfunction.

---

CRP and Homocysteine: Two Markers That Often Move Together

CRP rarely tells the full inflammatory story in isolation. Homocysteine — an amino acid produced during methionine metabolism — also tends to rise when folate or B12 are insufficient, and elevated homocysteine is independently associated with preeclampsia, placental abruption, and neural tube defects. In population studies, high-homocysteine and high-CRP pregnancies carry additive risk for adverse outcomes compared to either marker elevated alone.

The pathway linking the two is partly mechanistic: elevated homocysteine drives endothelial oxidative stress, which amplifies NF-κB signaling, which in turn upregulates IL-6 and therefore CRP. For a detailed look at homocysteine interpretation, our article on what causes homocysteine to be out of range covers optimal thresholds and the MTHFR-methylation connection.

---

What This Means for Your Formula

Ones does not offer a "pregnancy supplement" formula — and for good reason. Pregnancy-specific supplementation should be directed by an OB or midwife, and any formula requires medical oversight in that context. That said, the underlying mechanisms that drive CRP elevation in pregnancy — IL-6 signaling, hepatic acute-phase response, endothelial inflammatory tone — are the same mechanisms that Ones targets with its inflammation-relevant actives for non-pregnant adults.

Omega-3 (EPA/DHA): At doses of 1,800–2,700 mg EPA/DHA daily, fish oil supplementation consistently lowers hs-CRP in non-pregnant adults by an average of 0.3–0.5 mg/L in randomized controlled trials (Calder, Biochimica et Biophysica Acta 2015; PMID: 25149823). In pregnancy, omega-3 supplementation has been associated with a modest reduction in preterm birth risk and is not contraindicated, but dosing should be confirmed with an obstetric provider.

Vitamin D3 + K2 (MK-7): Vitamin D insufficiency (serum 25-OH-D below 30 ng/mL) is associated with significantly higher CRP in cross-sectional and prospective studies, and deficiency during pregnancy is associated with increased preeclampsia risk. The Ones formula pairs D3 with MK-7 because K2 directs calcium toward bone rather than soft tissue — a mechanism that becomes especially relevant in the second and third trimesters when fetal skeletal mineralization draws heavily on maternal calcium stores.

Liver Support blend: Chronic low-grade inflammation and elevated CRP are often compounded by impaired hepatic clearance of inflammatory mediators. The Ones Liver Support system blend is formulated to support phase I and II detoxification pathways, which help the liver clear cytokine-driven oxidative byproducts — relevant for anyone with persistently elevated hs-CRP outside of pregnancy.

For broader context on what the research says about supplements and CRP specifically in women, see our article on what supplements affect CRP in women.

---

Key Takeaways

• CRP rises in every healthy pregnancy. Expect hs-CRP between 0.5 and 8 mg/L depending on trimester — driven by placental cytokines, estrogen, and progressive placental growth, not pathology.
• Above 10 mg/L always warrants investigation. Preeclampsia, urinary tract infection, chorioamnionitis, and autoimmune flare are the primary conditions to exclude.
• Delivery causes a transient CRP spike. Cesarean section can push CRP above 60 mg/L; the marker should be declining by day 5 postpartum and back near baseline by 6–12 weeks.
• Standard non-pregnant reference ranges do not apply. Interpreting a third-trimester CRP of 6 mg/L as "high risk" is a clinical error; always apply trimester-specific context.
• Homocysteine and CRP should be read together. Combined elevation carries additive risk for adverse pregnancy outcomes and suggests inadequate B-vitamin status alongside inflammatory signaling.
• HPA axis changes amplify the picture. The dramatic cortisol and CRH shifts of late pregnancy modulate — but do not suppress — the CRP rise, creating interpretive complexity for women with pre-existing adrenal conditions.

This article is for informational purposes only and does not constitute medical advice. Always consult your obstetrician or healthcare provider before making any changes to your supplement regimen during pregnancy.